Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy.
- Garbino J Division of Infectious Disease, Dept. of Internal Medicine, University Hospital Geneva, 24 rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland. jorge.garbino@hcuge.ch
- Rohner P
- Kolarova L
- Ondrusova A
- Lew D
- 2003-10-18
Published in:
- Infection. - 2003
Adult
Aged
Antifungal Agents
Aspergillosis
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Fungal
Follow-Up Studies
Fungemia
Humans
Lung Diseases, Fungal
Male
Microbial Sensitivity Tests
Middle Aged
Pyrimidines
Sampling Studies
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome
Triazoles
Voriconazole
English
BACKGROUND
The incidence of fungal infections, including those due to Aspergillosis species has continued to increase in recent years. Invasive aspergillosis remains an important cause of morbidity and mortality, despite therapeutics interventions.
PATIENTS AND METHODS
We reported five cases of invasive pulmonary aspergillosis treated with voriconazole failing to respond to conventional treatments.
RESULTS
The clinical and radiological resolution of pulmonary aspergillosis reported in these cases following therapy with voriconazole is remarkable, considering the infections had proved refractory to standard antifungal therapies. Long-term therapy (in two cases > or = 1 year, in one case 6 months) was very well tolerated by patients who were unable to tolerate other antifungal agents.
CONCLUSION
Therapy with voriconazole offers a new therapeutic option for otherwise difficult-to-treat infections and the potential to significantly improve the management of Aspergillosis infections.
The incidence of fungal infections, including those due to Aspergillosis species has continued to increase in recent years. Invasive aspergillosis remains an important cause of morbidity and mortality, despite therapeutics interventions.
PATIENTS AND METHODS
We reported five cases of invasive pulmonary aspergillosis treated with voriconazole failing to respond to conventional treatments.
RESULTS
The clinical and radiological resolution of pulmonary aspergillosis reported in these cases following therapy with voriconazole is remarkable, considering the infections had proved refractory to standard antifungal therapies. Long-term therapy (in two cases > or = 1 year, in one case 6 months) was very well tolerated by patients who were unable to tolerate other antifungal agents.
CONCLUSION
Therapy with voriconazole offers a new therapeutic option for otherwise difficult-to-treat infections and the potential to significantly improve the management of Aspergillosis infections.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1007/s15010-003-3176-4
- PMID 14562948
- Persistent URL
- https://folia.unifr.ch/global/documents/26861
Statistics
Document views: 13
File downloads:
- fulltext.pdf: 0